Welcome to our dedicated page for KORU Medical Systems SEC filings (Ticker: KRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
KORU Medical Systems filings document a Nasdaq-listed medical technology issuer focused on large-volume subcutaneous infusion products. The disclosures identify its common stock, operating results, earnings-release exhibits, non-GAAP measures such as adjusted EBITDA and adjusted diluted EPS, and the Freedom System product family used in home self-administration and ambulatory infusion settings.
Its SEC record also covers proxy governance, board and stockholder-meeting procedures, officer and compensation arrangements, and material agreements tied to the business. Recent 8-K filings describe credit-facility arrangements and manufacturing and supply agreements for subassemblies, needle sets, and tubing products.
KORU Medical Systems, Inc. amended and restated its By-laws effective February 5, 2026. The Board updated the By-laws to address Securities and Exchange Commission rules on universal proxy cards and to reflect a periodic review of governance provisions.
The revisions enhance procedural mechanics and disclosure requirements for stockholders who nominate directors or submit proposals at annual and special meetings. Changes include additional disclosures, representations and acknowledgments from nominating or proposing stockholders and their nominees, and revised advance notice deadlines for director nominations when the number of directors increases under certain circumstances.
BlackRock, Inc. has filed a Schedule 13G reporting a passive ownership stake in Koru Medical Systems Inc. As of 12/31/2025, BlackRock reports beneficial ownership of 2,345,369 shares of Koru Medical common stock, representing 5.1% of the outstanding class.
BlackRock indicates sole voting power over 2,308,684 shares and sole dispositive power over all 2,345,369 shares, with no shared voting or dispositive power. The filing states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Koru Medical, reflecting a non-activist, investment-focused position.
KORU Medical Systems reported that its Chief Technology Officer, Eric Schiller, received new equity awards on January 2, 2026. He was granted 76,426 shares of common stock at a price of $0, described as restricted stock issued as an employment inducement award that will vest 25% annually starting on January 2, 2027. He was also granted an option to buy 232,297 shares of common stock with an exercise price of $5.7 per share, with one-fourth of the option scheduled to vest on January 2, 2027 and on each of the first, second and third anniversaries of that date.
KORU Medical Systems, Inc. filed a Form 3 for Chief Technology Officer Eric Schiller reporting his initial beneficial ownership in the company. As of the event date of 12/29/2025, the filing shows he beneficially owns 0 shares of common stock, held directly. A Form 3 is an initial statement of ownership that insiders must file when they become subject to reporting rules.
KORU Medical Systems, Inc. reported that it has released a press release with certain preliminary financial results for the fiscal quarter and full year ended December 31, 2025. These figures are based on the company’s current estimates and may change after completion of its normal closing and review procedures. The details of the preliminary results are provided in the press release included as Exhibit 99.1. The company specifies that this information is being furnished rather than filed under securities laws, which affects how it is incorporated into other regulatory documents.
KORU Medical Systems, Inc. granted its Chief Financial Officer, Thomas Adams, an award of 75,000 restricted stock units (RSUs)
One-fourth of the RSUs will vest on January 2, 202775,000 derivative securities$0 per unit
KORU Medical Systems, Inc. is registering shares of its common stock tied to an equity package for its incoming Chief Technology Officer, Eric Schiller. The filing covers 76,426 shares of restricted common stock and common stock issuable upon exercise of options covering 232,297 shares, all granted as a material inducement for him to accept the CTO role. These awards are subject to vesting and potential acceleration under individual agreements. The company also restates its standard provisions to limit director liability and to indemnify directors and officers to the maximum extent allowed under Delaware law and the federal securities laws.
KORU Medical Systems, Inc. (KRMD) reported an insider ownership update on a Form 4 filed by multiple reporting persons identified as a director and 10% owner. On 11/26/2025, a transaction coded "J(1)" involved the disposition of 41,000 shares of common stock at a stated price of $0. Following this transaction, the filer reports 5,830,335 shares of common stock beneficially owned indirectly through Horton Capital Partners Fund, LP, and an additional 517,200 shares of common stock beneficially owned directly. The filing includes customary disclaimers that it should not be construed as an admission of beneficial ownership or of any filing obligation.
KORU Medical Systems, Inc. entered into an Amended and Restated Manufacturing and Supply Agreement with Command Medical Products, Inc. on November 19, 2025. Effective as of January 1, 2024, the agreement replaces a prior manufacturing and supply agreement dated November 11, 2020.
Under the agreement, Command will manufacture and supply KORU’s subassemblies, needle sets and tubing products according to KORU’s specifications and purchase orders. The agreement runs through December 31, 2026 and automatically renews for one-year terms unless either party elects not to renew under its terms.
Either party may terminate the agreement for an uncured material breach within 45 days, upon the other party’s bankruptcy or insolvency, or as otherwise provided. The agreement also sets out terms for pricing and payment, rebates, purchase commitments based on KORU’s forecasts, and includes customary provisions covering delivery, inspection, warranties, quality management, business continuity, handling and transport, intellectual property, confidentiality and indemnification.
KORU Medical Systems (KRMD) reported Q3 2025 results with net revenues of $10.4 million, up 27.2% year over year. Core revenue reached $9.8 million (up 29.7%), driven by international core growth of 229.6%, while domestic core declined 5.0% due to ordering shifts and inventory reductions at a U.S. distributor.
Gross profit was $6.3 million, up 20.8%, with gross margin of 60.2% versus 63.4% a year ago, reflecting higher manufacturing costs, geographic mix, and tariff charges. Operating expenses were $7.1 million, modestly higher than last year. Net loss narrowed to $0.8 million from $1.6 million.
For the nine months, revenue was $30.2 million (up 21.9%) with a net loss of $2.2 million versus $4.5 million last year. Cash and cash equivalents were $8.5 million as of September 30, 2025, and there were no outstanding borrowings under the $5 million revolver or $5 million term facility. Management noted tariff-related charges of $0.1 million in Q3 and expects an annualized gross margin impact of less than 100 basis points.